Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada (vol 25, pg 32, 2018)

被引：0
|
作者：
Chua, A.
Perrin, A.
Ricci, J. F.
Neary, M. P.
Thabane, M.
机构：
来源：
CURRENT ONCOLOGY | 2018年 / 25卷 / 04期
关键词：
D O I：
10.3747/co.25.4233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E354 / E355
页数：2
相关论文
共 50 条
  • [21] Development and validation of a grading system for the quality of cost-effectiveness studies (vol 41, pg 32, 2003)
    Chiou, CF
    Hay, JW
    Wallace, JF
    Bloom, BS
    Neumann, PJ
    Sullivan, S
    Yu, HT
    Keeler, EB
    Henning, JM
    Ofman, JJ
    MEDICAL CARE, 2003, 41 (03) : 446 - 446
  • [22] Cost-effectiveness and Budget Impact of Treatment With Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain (vol 71, pg 1027, 2018)
    de Labry Lima, Olry
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (12): : 1091 - 1091
  • [23] A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States (vol 21, pg 835, 2018)
    Nuijten, M.
    Marczewska, A.
    Torres, Araujo K.
    Rasouli, B.
    Perugini, M.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (09) : 845 - 845
  • [24] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access (vol 10, pg 887, 2018)
    Aguiar, Pedro, Jr.
    Del Giglio, Auro
    Perry, Luke Alastair
    Penny-Dimri, Jahan
    Babiker, Hani
    Tadokoro, Hakaru
    Lopes, Gilberto, Jr.
    De Mello, Ramon Andrade
    IMMUNOTHERAPY, 2018, 10 (14) : 1285 - 1285
  • [26] Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study
    Zuidema, Sander
    Desar, Ingrid M. E.
    van Erp, Nielka P.
    Kievit, Wietske
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1994 - 2001
  • [27] Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018 (vol 38, pg 1135, 2020)
    Kim, David D.
    Silver, Madison C.
    Kunst, Natalia
    Cohen, Joshua T.
    Ollendorf, Daniel A.
    Neumann, Peter J.
    PHARMACOECONOMICS, 2020, 38 (12) : 1377 - 1377
  • [28] Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand (vol 124, pg 233, 2018)
    Jaine, Richard
    Kvizhinadze, Giorgi
    Nair, Nisha
    Blakely, Tony
    LUNG CANCER, 2020, 144 : 98 - 98
  • [29] Role and cost-effectiveness of adrenal imaging and image-guided FNA cytology in the management of incidentally discovered adrenal tumours (vol 25, pg 4559, 2005)
    Lumachi, F
    Basso, SMM
    Borsato, S
    Tregnaghi, A
    Zucchetta, P
    Marzola, MC
    Cecchin, D
    Bui, F
    Fabia, G
    ANTICANCER RESEARCH, 2006, 26 (1A) : 446 - 446
  • [30] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
12345